Enterprise Products Partners L.P. Common Stock (EPD)

Long-Term Debt

$31.91B

Quarterly · Period ending: · USD

EPD logo

EPD Long-Term Debt

Latest reported$31.91B
EPD Quarterly Long-Term Debt ($75.00M → $31.91B)
High-resolution chart · PNG

EPD long-term debt history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Enterprise Products Partners L.P. Common Stock Long-Term Debt — Quarterly (USD)
Period endingLong-Term Debt (USD)
31,906,000,000
31,621,000,000
33,204,000,000
31,808,000,000
31,454,000,000
29,486,000,000
31,112,000,000
31,106,000,000
28,655,000,000
28,618,000,000
27,771,000,000
27,784,000,000
27,443,000,000
27,439,000,000
26,892,000,000
26,548,000,000
26,892,000,000
26,889,000,000
28,474,000,000
28,132,800,000
27,148,600,000
27,145,900,000
28,861,500,000
28,537,000,000
27,285,200,000
27,855,900,000
25,814,800,000
25,639,200,000
26,385,000,000
24,181,600,000
24,678,100,000
22,508,500,000
23,020,200,000
23,016,400,000
21,713,700,000
21,710,900,000
20,026,500,000
21,123,000,000
21,120,900,000
21,121,200,000
21,922,100,000
21,919,800,000
20,676,900,000
20,840,700,000
20,892,900,000
20,192,200,000
19,157,400,000
17,706,500,000
17,062,900,000
17,467,800,000
16,226,500,000
16,481,600,000
16,429,600,000
16,393,700,000
14,655,200,000
14,747,200,000
13,346,700,000
13,570,800,000
14,029,400,000
14,108,700,000
13,544,700,000
13,273,600,000
13,281,200,000
12,704,800,000
12,416,500,000
10,915,700,000
12,427,900,000
9,198,300,000
9,224,300,000
9,307,300,000
11,637,900,000
8,434,201,000
7,768,507,000
7,518,496,000
6,906,145,000
6,771,988,000
6,259,715,000
5,448,685,000
5,295,590,000
4,884,261,000
4,821,401,000
4,396,315,000
4,833,781,000
4,788,840,000
4,568,447,000
4,128,303,000
4,266,236,000
4,972,150,000
1,402,370,000
2,195,876,000
1,899,548,000
1,874,577,000
1,859,607,000
1,986,636,000
2,231,463,000
1,313,507,000
1,223,552,000
1,168,596,000
855,278,000
855,443,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.